High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- PSA Response Rate
研究概览
简要总结
The purpose of this study is to determine the efficacy of BAT and carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
详细描述
Androgen deprivation therapy (ADT) remains the mainstay of prostate cancer treatment. Though an effective therapy initially, the side effects of ADT are numerous and treatment resistance is inevitable. Castrate-refractory prostate cancer (CRPC) progresses via adaptive mechanisms that allow ongoing androgen receptor (AR) signalling despite castrate levels of androgens.
The concept of cycling between supra- and sub physiological levels of testosterone has been tested recently in studies of "bipolar androgen therapy" (BAT) in which patients are given high dose testosterone in combination with androgen deprivation therapy (ADT) via an LHRH agonist/antagonist. Studies of BAT using IM testosterone have been promising both in terms of PSA responses and quality of life improvements. Additionally, these early phase studies suggest the potential for re-sensitisation to novel anti-androgen therapies.
Though responses have been positive in these early studies a proportion of men fail to respond and data to guide patient selection is lacking. There are data to suggest that patients with DNA repair deficits may be particularly responsive to BAT. Whether these changes serve as predictors of response is unknown as the effect of BAT on the tumour, its microenvironment and peripheral circulating tumour DNA has not been studied in detail. Information on treatment effects may be key to appropriate patient selection for this treatment.
The aim of this study is to assess based on the pre-clinical studies, the combination with carboplatin
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males with histologically confirmed adenocarcinoma of the prostate
- •Confirmed HRD (Homologous recombination defect) in germline and/or somatic DNA analysis (tumour or blood), by a validated assay (see Appendix 1). Mutations in HR genes not listed in appendix 1 will be considered in literature suggests pathogenicity. A maximum of 10 uncharacterised or heterozygous mutations will be included.
- •Age ≥ 18 years
- •ECOG performance status ≤ 1
- •Rising PSA confirmed on two sequential tests ≥1 week apart and a minimum value of 2 ug/L despite castrate levels of testosterone
- •Serum testosterone < 1.7 nmol/L and on an LHRH agent or post orchidectomy ≥ 1 year.
- •Washout of ≥ 4 weeks from prior line of treatment, radiotherapy or surgery (aside from LHRH agent)
- •Adequate bone marrow function (platelets > 100 x 109/L, ANC > 1.5 x 109/L, Hb >100)
- •Adequate liver function (ALT/AST < 1.5 x ULN, bilirubin < 2 x ULN)
- •Adequate renal function (creatinine clearance > 50 ml/min)
- •Adequate cardiac function and reserve after cardiology assessment
- •Archived tissue sample available or willingness to undergo fresh biopsy
- •Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
- •Signed, written informed consent
排除标准
- •Contraindications to investigational product
- •Pain due to metastatic prostate cancer requiring opioid analgesics
- •Evidence of disease progression in sites or extent that, in the opinion of the investigator, would put the patient at risk from testosterone therapy and its potential for initial tumour flare (eg: femoral metastasis at risk of fracture, ureteric obstruction due to nodal disease or cord compression due to spinal metastases).
- •Previous treatment with platinum chemotherapy and/or a PARP inhibitor. However up to 8 men with prior treatment to these agents will be included as an exploratory cohort.
- •Life expectancy of less than 3 months.
- •Brain metastases or leptomeningeal disease
- •History of thromboembolic event and not currently on anticoagulation
- •Prior myocardial infarction or unstable angina within 2 years of study entry
- •Haematocrit ≥ 50%, untreated severe obstructive sleep apnoea or poorly controlled heart failure (NYHA >1)
- •History of another malignancy within 5 years prior to registration. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 5 years after definitive primary treatment.
- •Concurrent illness, including severe infection that may jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety.
- •Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.
研究组 & 干预措施
High dose testosterone + Carbolplatin
500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5
干预措施: Testosterone Enanthate 100 MG/ML Injectable Solution (Drug)
High dose testosterone + Carbolplatin
500mg IM enanthate every 4 weeks in combination with ongoing LHRH agent (unless post-orchidectomy) plus Carboplatin AUC 5
干预措施: Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5 (Drug)
结局指标
主要结局
PSA Response Rate
时间窗: 1 year
\>/= 50% fall from baseline PSA
次要结局
- Radiological Response Rate(1 year)
- Safety and Tolerability (Frequency of adverse events as assessed by NCI CTCAE v4.0)(1 year)
- Time to PSA progression(1 year)
研究者
Anthony Joshua, FRACP
Principal Investigator
St Vincent's Hospital, Sydney